Correction RangesWaveLight's Allegretto Wave LASIK technology is approved in the United States for the correction of the following refractive errors:
Wavefront-guided Allegretto Wave:
Up to -7.00 D of myopia
Up to -3.00 D of myopic astigmatism
Wavefront-optimized Allegretto Wave:
Up to -12.00 D of myopia
Up to -6.00 D of myopic astigmatism
Up to +6.00 D of hyperopia
Up to +5.00 D of hyperopic astigmatism
Results of clinical trialsApproval of WaveLight's Allegretto Wave technology for LASIK surgery in the United States is based on the results of clinical trials of the company's wavefront-optimized procedure mandated by the U.S. Food and Drug Administration (FDA).
In the clinical trial for the correction of nearsightedness, uncorrected visual acuity (UCVA) results 3 months after surgery were:
84.4% of the eyes were 20/20 or better.
98.0% of eyes were 20/40 or better.
In the clinical trial for the correction of farsightedness (with and without astigmatism) UCVA results 6 months after surgery were:
67.5% of the eyes were 20/20 or better.
95.3% of the eyes were 20/40 or better.
More information
To learn more about WaveLight's Allegretto Wave LASIK technology, visit
www.allegretto-wave.com.